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PRIMARY LYMPHOMA OF THE 
CENTRAL NERVOUS SYSTEM
A clinical-pathological and immunohistochemical 
study of ten autopsy cases 
Henrique Costa1, Marcello Franco2, Myriam Dumas Hahn3
ABSTRACT - Context:P r i m a ry central nervous system lymphomas (PCNSL) are a rare subgroup of lymphomas
generally associated with HIV and EBV. Objective: To study ten autopsy cases of PCNSL, to describe the
n e u ropathological findings, to characterize the phenotype of the neoplastic cells, to detect EBV in the
lesion and to compare the findings with the clinical and laboratory data of the patients. Method: T h e
clinical, histological and immunohistochemical data of ten cases of PCNSL, eight cases from patients with
AIDS, identified among 265 autopsies of these patients were analyzed. Results: Seven patients were males
and the mean age was 40.9 years. The most frequent symptomatology was focal neurologic deficit (70%).
Six patients presented with only one lesion. Histologically, densely cellular and polymorphous neoplasms
with angiocentrism were observed, in 90% of cases. An association with other diseases was observed in
four cases. Most patients had diffuse large B cell non-Hodgkin’s lymphoma. EBV was detected by immuno-
histochemistry in only one case. The lack of detection of the virus might have been due to the long time
of fixation of the brain which might have inactivate epitopes there f o re compromising the testing.
Conclusion: In the present series, PCNSL presented with focal symptoms, with unifocal or multifocal lesions,
with a predominant B-cell CD20 positive phenotype, rarely associated with EBV.
KEY WORDS: primary central nervous system lymphoma, neuro p a t h o l o g y, immunohistochemistry, acquire d
immunodeficiency syndrome.
Linfoma primário do sistema nervoso central: estudo clínico-patológico e imuno-histoquímico
de dez casos de necropsia
RESUMO - Contexto: Linfoma primário do sistema nervoso central (LP-SNC) é raro subgrupo de linfomas
relacionado à AIDS, geralmente associado EBV. Objetivo: Identificar os achados clínico-patológicos dos
pacientes com LP-SNC. Método: Foram analisados dados clínicos, histológicos e imuno-histoquímicos de
dez necrópsias de LP-SNC, oito deles de pacientes com AIDS, identificados entre 265 autopsias destes.
Resultados: Sete pacientes foram masculinos e a idade média foi 40,9 anos. A sintomatologia neurológi-
ca mais freqüente era focal (70%). Seis exibiram lesão única. Histologicamente, eram neoplasias densa-
mente celulares e polimorfas, com angiocentrismo em 90% dos casos. Em quatro  casos, houve associação
com outras afecções. A maioria dos casos foi de linfoma não-Hodgkin difuso de grandes células B. A pesquisa
para EBV foi positiva em um caso. Conclusão: P redominaram os LP-SNC associados à AIDS, com sintoma-
tologia focal, lesão em massa ou multifocal, com predominância de células B CD-20.
PA L AV R A S - C H AVE: linfoma primário do sistema nervoso central, achados neuropatológicos, imuno-histo-
química, síndrome da imunodeficiência adquirida.
P r i m a ry central nervous system lymphomas (PCN S L )
a re a rare group of neoplasms, accounting for about
0.3 to 1.5% of all intracranial tumors and for 0.7 to
2% of lymphomas1. These tumors are generally asso-
ciated with immunosuppression due to either the use
of immunosuppressive dru g s2, human immunodefi-
ciency virus (HIV) infection3 , 4 or congenital disord e r s
such as Wiskott-Aldrich syndro m e5. PCNSL differ fro m
extranodal lymphomas in terms of patient surv i v a l ,
p redisposing factors, histological subtypes and diff i-
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culties in the classification according to the Wo r k i n g
F o rmulation, the Kiel criteria and the revised Euro-
pean-American Lymphoma (REAL) system. In view of
their restriction to a non-lymphoid organ, among
other reasons, PCNSL have been considered a sepa-
rate entity whose prognosis is generally worse than
that of systemic lymphomas6. With the advent of AIDS
and the introduction of organ transplants, the inci-
dence of PCNSL has been increasing. These tumors
c u rrently re p resent an important subgroup of lym-
phomas2,4. In patients with AIDS, PCNSL are the sec-
ond most common lesion with a mass eff e c t4 and the
most frequent noninfectious cause of death7. The
tumor re p resents the fourth cause of death in this
g roup of patients8. PCNSL show a male/female ratio
of 1.5 to 1, whereas the T subtype presents a ratio of
7 : 19. The clinical manifestations are indistinguishable
f rom cerebral toxoplasmosis and include loss of con-
sciousness and focal neurologic deficits1 0. In the case
of meningeal involvement, the tumor manifests as a
meningeal syndro m e1 1 , 1 2. Most PCNSL involve the ba-
sal nuclei or the frontal and parietal lobes, and pre s-
ent as homogenous mass lesions with ring-like zone
of contrast enhancement and perilesional edema.
The neuroimaging diff e rential diagnosis with cere-
bral toxoplasmosis is difficult10. The lesions are mul-
tifocal, bilateral or periventricular and may extend
to the subarachnoid space or ventricular cavity1 3. The
m a c roscopic findings are variable1 4. Some tumors pre-
sent as well-defined masses with a homogenous cut
s u rface. Other lesions are poorly demarcated, dif-
fusely infiltrating, showing areas of softening, hem-
o rrhage and necro s i s1 5. In immunocompetent pa-
tients, PCNSL are more superficial and located in the
white and/or gray matter1 6, or exclusively in the sub-
arachnoid space17.
The histopathological findings of PCNSL are sim-
ilar to those of systemic non-Hodgkin’s lymphomas
and include densely cellular lesions comprised by
atypical lymphoid cells1 3 with an angiocentric pat-
tern at the margins of the infiltrate and a rich retic-
ulin network dissociating the vascular wall1 8. In volu-
minous tumors, the areas of necrosis can be exten-
sive. Mitotic activity is high and hemorrhage is com-
mon. Neoplastic cells may invade normal adjacent
s t ru c t u res. There f o re subependymal infiltration ex-
tending into the ventricular cavity and subarachnoid
space are not uncommon1 4. The oncogenesis of PCNSL
is still controversial. The site of origin of these lym-
phomas and the oncogenetic mechanisms are still
u n c l e a r, especially because the tumor develops fro m
and is restricted to a non-lymphoid organ without
lymphatic vessels19. It might occur due to the devel-
opment of a monoclonal proliferation from a pre -
existing inflammatory lesion, similar to the mecha-
nism underlying the origin of MALT lymphoma fro m
Helicobacter pylori-induced gastritis. This hypothe-
sis is supported by the demonstration of inflamma-
t o ry lesions preceding the development of PCNSL2 0 , 2 1.
Other authors suggest that non-neoplastic lympho-
cytes might be targeted to the CNS by a viral infec-
tion, more notably HTLV-1 or EBV, with the possible
later occurrence of clonal neoplastic transform a t i o n
of these cells12. In the case of immunodepressed pa-
tients, one may speculate that the lack of control of
T cells over EBV present in patients with AIDS pro-
motes the reactivation of EBV infection, leading to
the proliferation of B cells, induction of oncogenes
and gene re a rrangements, and finally to the devel-
opment of PCNSL2 2. There f o re in patients with AIDS,
infection with EBV is suggested to be the most like-
ly oncogenetic mechanisms since the EBV genome is
found in more than 95% of these tumors and in less
of 20% of PCNSL not associated with AIDS2 3 - 2 5. Herpes
v i rus genomes such as HHV-6 or HHV-8 have been
identified in some cases, suggesting that these or
other herpes viruses may predispose to the develop-
ment of primary lymphoma, even in immunocompe-
tent patients2 3. HIV-infected subjects show a 60 to
100 times higher risk of developing malignant lym-
phoma, which re p resents a diagnostic criterion for
AIDS5.
Based on the above observations, we studied ten
autopsy cases of PCNSL to more accurately describe
the neuropathological findings and to characterize
the phenotype of the neoplastic cells, to test the pre s-
ence of EBV and to compare the morphological find-
ings with the clinical and laboratory data of the
patients.
METHOD
A total of 265 autops ies of patients perf o rmed at the
S e rvice of Pathological Anatomy, Department of Pathology,
Antônio Pedro University Hospital, Federal University
Fluminense, between 1987 and 1996 were revised and 10
cases of PCNSL were selected (3.7%).
P reparation of the material and fixation – The autop-
sy was complete in all cases and the CNS was fixed in 30%
f o rmalin for 21 days and then examined. The cerebral hemi-
s p h e res were studied in approximately 1.0-cm thick coro-
nal sections and in 0.5- to 1.0-cm perpendicular sections cut
from the cerebral trunk and cerebellar hemispheres. 
Fragments re p resentative of the lesions were embed-
ded in paraffin, cut into 5-µm thick sections, stained with
hematoxylin-eosin and for reticulin fibers. 
I m m u n o h i s t o c h e m i s t ry– 5 -µm thick CNS sections were
mounted on slides previously treated with 3-aminopropy-
ltriethoxysilane (Sigma, A3648). After incubation in an oven
at 60ºC for about 18 h, the sections were deparaffinized in
xylene and hydrated in decreasing ethanol concentrations.
Next, the specimens were incubated in two baths of 3%
oxygenated water in methanol for 15 min each to inhibit
endogenous peroxidase and washed with Tris buff e r, pH
7.4. For antigen retrieval, the sections were immersed in
citrate buff e r, pH 6.0, and heated in a microwave oven for
5 min at maximum potency. Pre s s u re chamber was used to
CD3, CD20, CD15, KAPPA, LAMBDA e EBV antibodies. To
inhibit nonspecific binding, the sections were incubated in
a Tr i s - b u ff e red solution of 1% skim milk (w/v) and 1%
bovine serum albumin (w/v) in a humid chamber for 1 h at
room temperature. Next, the sections were incubated over-
night in a humid chamber at 4ºC with the following pri-
m a ryantibodies: rabbit anti-human CD3 polyclonal (Dako,
A 0452, diluted 1/200), mouse anti-human CD20 monoclon-
al (Dako, M 0755, diluted 1/250), mouse anti-human CD15
(Dako, M 733, diluted 1/150), mouse anti-human Kappa
monoclonal (Sigma, K-4377, diluted 1/4000), mouse anti-
human Lambda monoclonal (Sigma, L-6522, diluted 1/4000),
and mouse anti-EBV monoclonal (Dako, M 0897, diluted
1/2500).
For the anti-CD30, anti-CMV and anti-GFAP antibodies,
the sections were trypsinized, nonspecific binding of the
antibodies was blocked and the specimens were incubat-
ed in a humid chamber at 37ºC with the following primary
antibodies: mouse anti-human CD30 monoclonal antibody
(Dako, M 751, diluted 1/100), mouse anti-CMV monoclon-
al antibody (Dako, M 854, diluted 1/100), and rabbit anti-
GFAP polyclonal antibody (Dako, Z 0334, diluted 1/400).
Next, the sections were washed three times in Tris buff e r
for 10 min each and incubated with the biotinylated sec-
o n d a ry antibodies: goat anti-rabbit immunoglobulins (Dako,
E 432, diluted 1/200) or rabbit anti-mouse immunoglobu-
lins (Dako, E 0354, diluted 1/200) for 1 h in a humid cham-
ber at 37ºC. The primary and secondary antibodies were
diluted in Tr i s - b u ff e red1% bovine serum albumin (w/v).
After three washes in Tris buffer for 10 min each, the sec-
tions were incubated with the stre p t a v i d i n - b i o t i n - p e ro x i-
dase complex (Dako, K 0377) for 45 min in a humid cham-
ber at room temperature, washed again three times in Tr i s
b u ff e r, and the peroxidase reaction was developed with
diaminobenzidine (Sigma, 5637) and oxygenated water.
The sections were counterstained with Mayer’s hematoxylin.
The antibodies used are shown in Table 1. 
RESULTS
General clinical data and laboratory exams –T h e
g e n d e r, age, risk behavior, clinical data and comple-
m e n t a ry exams of the patients are summarized in Ta-
ble 2. Seven patients were males and three were
females, with age ranging from 24 to 64 years (mean
±s t a n d a rddeviation: 40.9±11.8 years). Neuro l o g i c a l
signs or symptoms were observed in all but one case,
with a predominance of focal neurological deficit in
seven patients. The time between the discovery of
HIV positivity and the diagnosis of PCNSL ranged fro m
6 months to 3 years.
G ross findings – B rown-grayish, poorly demarc a t-
ed lesions with areas of necrosis, comprised by soft,
fleshy to friable tissue, were identified in the basal
nuclei (Fig 1) and thalamus of six, in the cere b r a l
t runk of four, in the cerebellar hemisphere of thre e ,
and in the cortex and corpus callosum of two pa-
tients. Multiple lesions were observed in six cases,
with the number of lesions ranging from 2 to 4. In
three cases, only one lesion was identified. 
In one case, the gross findings diff e red from those
observed in other cases. The tumor lesion was char-
acterized by a whitish color and homogenous surf a-
ce with a fish-flesh appearance, and involved stru c-
t u res of the midline and deep gray matter, extend-
ing to the corpus callosum and adjacent white mat-
ter (Fig 2). Another case was characterized by the
e n l a rgement of the nerve roots and cranial nerv e s ,
and opacity of the leptomeninges. Analysis of the
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Table 1. Panel of antibodies.
Primary Diluition Source Code Origin Secundary Antigen retrieval
antibody antibodies procedure
CD30 1/100 Dako M 751 Mouse R x M * Trypsin
CD15 1/150 Dako M 733 Mouse R x M * MW/PC*
CD3 1/200 Dako A 0452 Rabbit G x R*** MW/PC*
CD20 1/250 Dako M 0755 Mouse R x M * MW/PC*
Kappa 1/4000 Sigma K-4377 Mouse R x M * MW/PC*
Lambda 1/4000 Sigma L-6522 Mouse R x M * MW/PC*
EBV 1/2500 Dako M 0897 Mouse R x M * MW/PC*
CMV 1/100 Dako M 854 Mouse R x M * Trypsin
GFAP 1/400 Dako Z 0334 Rabbit G x R*** Trypsin
*Ig Rabbit anti-Ig Mouse; **MW/PP, Microwave/Pressure chamber ; ***Ig Goat anti-Ig Rabbit.
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Table 2. Identification, clinical data, risk behavior and complementary exams of 10 autopsy cases of CNS primary lymphoma diag -
nosed.
Case Age Gender Risk behavior HIV Time of Clinical data Neurological signs
(Y/O) evolution
(months)
1 64 F Hemotransfusion + 10 Loss weight, fever, Focal neurologic deficit,
N87-297 diarrhea, hemorrhage convulsion, coma
2 35 M NE + NE Loss weight, fever, No neurological signs.
N88-422 diarrhea, pulmonary
infection
3 46 M Promiscuous + 12 Loss weight, fever, Paraplegy, dysfunction
N89-009 diarrhea, pneumocystosis of sphincter
4 28 M NE + 12 Loss weight, fever, Meningeal syndrome, 
N89-224 diarrhea, pneumocystosis, coma
Kaposi’s sarcoma
5 38 M NE + 8 Loss weight, fever, Focal neurologic deficit, 
N91-013 diarrhea, pneumocystosis meningeal syndrome
6 42 M Hemotransfusion + 13 Loss weight, fever, Focal neurologic deficit
N91-113 Homosexualism diarrhea, pulmonary
infection, Kaposi’s sarcom
7 24 M Hemotransfusion + 24 Loss weight, fever, Focal neurologic deficit, 
N93-041 diarrhea,pneumocystosis, convulsion
digestive hemorrhage
8 33 F Hemotransfusion + 36 Loss weight, fever, Focal neurologic deficits,
N95-163 Promiscuous diarrhea convulsion, headache, 
vomiting, meningeal 
syndrome, coma
9 50 M – – 4 – Focal neurologic deficit,
N95-205 headache, vomiting,
cerebellar syndrome
10 49 F – – 4 – Focal neurologic deficit, 
N96-326 p a r a p l e g y, vomiting, pain
in inferior extremities,
visual hallucinations, 
dysfunction of sphincter
NE, not especificated; +, positive; –, absent/negative.
Fig 1. Tumoral  involvement of basal nuclei (arrow), with hyper -
emic halo and compression of the lateral ventricle (LV) and
deviation of the central structures. 
Fig 2. Bilateral  tumoral masses in the basal nuclei (arrow) and
the corpus callosum, with compression of the lateral ventricle.
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various sections did not reveal any pare n c h y m a l
abnormalities.
Other important associated macroscopic findings
w e re cortical atrophy in four cases and cerebral ede-
ma accompanied by uncal and tonsillar herniation in
two (Table 3).
M i c roscopic findings –M i c roscopic examination
revealed densely cellular parenchymatous lesions in
nine cases (Fig 3A). These lesions were characterized
by atypical lymphoid cells, a central area of necrosis
and an angiocentric pattern at the periphery of the
infiltrate (Fig 3B), with a rich reticulin network dis-
sociating the vascular wall. Only one case did not pre-
sent the angiocentric arrangement.
In most cases, infiltration was diffuse and consist-
ed of a polymorphic infiltrate comprised pre d o m i n a n-
tly by large, sometimes bi- or multinucleated, immuno-
blast-like cells containing large, pleomorphic, vesicu-
lar nuclei, clearly visible nucleoli and scarce cytoplasm.
The mitotic count was high. In two cases the cellular
infiltration was made up by small lymphoid cells with
inconspicuous mitotic activity. Plasma cell diff e re n t i-
ation was also observed in one case (Table 4).
Gliosis was identified in all cases, especially at the
Fig 3. Histopathology of the non-Hodgkin large B-cell lymphoma. (A) Note dense sheet of typical
lymphocytes (HE; 40x). (B) Angiocentric pattern (arrow; V) of the tumoral involvement (HE; 5x).
Table 3. Gross findings at of 10 autopsy cases of CNS primary lymphomas.
Case External exam Nº tumoral Lobar Basal Cerebral Cerebellar Size
lesions lesion nuclei trunk hemisphere (major lesion)
1 Cortical atrophy / old infarct 3 – 1 1 1 1.5 x 1.0 cm
2 Congestion 1 1 – – – < 1.0 cm
3 NL 1 – – – – < 1.0 cm
4 Oedema / cerebral hernia 2 – 1 1 – 4.0 x 3.5 cm
5 Oedema / cerebral hernia 1 – 1 – – 6.0 x 4.0 cm
6 Cortical atrophy 2 – 2 – – 2.0 x 2.0 cm
7 Cortical atrophy 2 2 – – – 2.0 x 1.5 cm
Cavitary lesion
8 Cortical atrophy 4 – – – 2 3.0 x 2.5 cm
9 Mild oedema 4 – 2 1 1 5.0 x 4.0 cm
10* Mild oedema – – – – – –
NL, no lesions; *Absence of parenchymatous lesions. Enlargement of the nerve roots and cranial nerves.
Arq Neuropsiquiatr 2006;64(4) 981
p e r i p h e ry of the tumoral mass, and reactive astro c y-
tes were eventually observed within the tumor tissue.
Associated disorders – O p p o rtunistic infections
w e re observed in six cases: HIV-encephalitis (n=2),
CMV - encephalitis (n=2), cerebral toxoplasmosis (n=1)
and cerebral cryptococcosis (n=1) (Table 4).
Immunohistochemical findings – All cases but one
showed a B phenotype (CD20 positive); the remain-
ing case, from a HIV negative patient, was positive
for T-lymphocytes (CD3 positive). In addition, just one
case was CD30 positive and one case EBV positive
(Fig 4).
According to the REAL classification26, three cas-
es were classified as diffuse large B-cell non-Hodgkin’s
lymphoma, one case as lymphoplasmacytic non-Hod-
g k i n ’s lymphoma, one case as B-lymphoblast pre c u r-
sor non-Hodgkin’s lymphoma, and one case as periph-
eral T-cell non-Hodgkin’s lymphoma, not otherw i s e
specified. The three cases, in which no immunohis-
t o c h e m i s t ry could be perf o rmed, were classified as
probably diffuse large B-cell lymphoma.
Table 4. Classification and histopathologic findings at of 10 autopsy cases of CNS primary limphoma.
Case Classification (REAL) Necrosis Angiocentric Subependimal Associated
pattern infiltration infections
1 Lymphoplasmacytic NHL (low grade) Yes Yes Yes No
2 Diffuse large cell NHL Yes Yes No Cryptococcosis
HIV-E
3 Diffuse large cell NHL Yes Yes No No
4 Diffuse large B-cell NHL Yes Yes Yes HIV-E
5 Diffuse large cell NHL Yes Yes Yes No
6 Diffuse large B-cell NHL Yes Yes Yes No
7 Diffuse large B-cell NHL Yes Yes Yes CMV-E
Treated toxoplasmosis
8 Diffuse large B-cell NHL Yes Yes Yes CMV-E
9 B-lymphoblast precursor NHL No No Yes No
10 Peripheral T-cell NHL No Yes No No
not otherwise specified
NHL, non-Hodgkin’s lymphoma; HIV, human immunodeficiency virus; CMV, cytomegalovirus; E, encephalitis.
Fig 4. Immunoreactivity of  the neoplastic lymphoid cells for CD20. Note strong  membrane
pattern of positivity (IHC; 40x).
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DISCUSSION
In the present study, all tumors were only identi-
fied in the CNS, in agreement with the criteria for
the diagnosis of PCNSL which re q u i re that no lympho-
mas are detected in organs other than the CNS or
posterior region of the retina at the onset of neuro-
logical symptoms11,14. By definition, extranodal lym-
phomas are recognized as lymphoid tumors arising
f rom lymphoid cell-containing sites other than the
lymph nodes27.
M a c ro s c o p i c a l l y, the lesions were similar to those
of toxoplasmosis, a finding also re p o rted by Cirilo
and Rosenblum1 5. Similarly, neuroimaging does not
p e rmit a diff e rential diagnosis with cerebral toxo-
p l a s m o s i s4 and other methods are necessary for diag-
nosis conclusion2 8. Thus, in the present study, the
diagnosis of PCNSL was made only by microscopy.
In the present study, immunohistochemistry for
EBV revealed only one positive case in an AIDS pa-
tient. The lack of detection of the virus might have
been due to the long time of fixation of the brain
which might have inactivate epitopes there f o re com-
promising the testing.
Association with other CNS disorders was a fre-
quent finding in the present series. It might be spec-
ulated as proposed by Aderson et al.2 0 and Aozasa
et al.2 1 that the presence of HIV- or CMV-induced en-
cephalitis is responsible for B-cell hyperreactivity.
PCNSL continue to be a challenge in terms of their
morphology and oncogenesis. Molecular studies of
oncogenes and suppressor genes are still inconclu-
sive. These lymphomas develop in non-lymphoid or-
gans without lymphatic vessels, and as such re p re-
sent one of the main areas of neuro-oncological re-
search.
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